Related Experiment Video
Updated: Jun 28, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
280
CircRNAs in cancer therapy tolerance
Miao He1, Yunyan Pan2, Chongge You2
1The Second Hospital of Lanzhou University, Laboratory Medicine Center, Lanzhou 730030, PR China; The Second Clinical Medical School, Lanzhou University, Lanzhou 730030, PR China.
Summary
Circular RNAs (circRNAs) in serum show promise as noninvasive biomarkers for predicting cancer treatment resistance and outcomes. Further research aims to integrate circRNA profiling into clinical practice for personalized oncology.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Circular RNAs (circRNAs) are emerging as critical regulators in cancer.
- Serum circRNAs offer potential as noninvasive biomarkers due to their stability and abundance.
- Understanding circRNA roles is vital for advancing cancer diagnostics and treatment.
Purpose of the Study:
- To review the biogenesis, function, and clinical relevance of circRNAs in cancer.
- To highlight serum circRNAs as biomarkers for predicting tumor therapy resistance.
- To discuss challenges and future prospects of circRNA research in clinical oncology.
Main Methods:
- Comprehensive literature review of existing studies and clinical trials on circRNAs in cancer.
- Analysis of circRNA roles in oncogenesis, tumor progression, and treatment response.
- Evaluation of serum circRNAs for prognostic significance and resistance prediction.
Main Results:
- CircRNAs play complex roles in oncogenesis and influence patient response to chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
- Serum circRNAs demonstrate prognostic significance in predicting therapeutic outcomes and resistance mechanisms.
- CircRNA profiling has the capacity to inform personalized cancer treatment strategies.
Conclusions:
- Serum circRNAs are promising noninvasive biomarkers for early cancer diagnosis and therapy tolerance prediction.
- Standardized protocols for circRNA extraction and quantification are needed.
- Integrating circRNA profiling into clinical workflows can advance precision oncology and novel therapeutics.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K